Evidence map›Paper›PMID 30827277›Full record

ArticleInfectious diseases of poverty2019

HIV prevalence in suspected Ebola cases during the 2014-2016 Ebola epidemic in Sierra Leone.

William J Liu, Hai-Yang Hu, Qiu-Dong Su, Zhe Zhang, Yang Liu, Yu-Lan Sun, Xian-Da Yang, Da-Peng Sun, Shao-Jian Cai, Xiu-Xu Yang and 11 more

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Prevalence of viral hepatitis B and C in Sierra Leone-current knowledge and knowledge gaps: a narrative review.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

William J LiuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing, 102206, China. liujun@ivdc.chinacdc.cn.ORCID http://orcid.org/0000-0003-3605-4070
Hai-Yang HuJiangsu Provincial Center for Disease control and Prevention, Nanjing, 210009, China.
Qiu-Dong SuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing, 102206, China.
Zhe ZhangBeijing Institute of Biotechnology, Beijing, 100071, China.
Yang LiuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing, 102206, China.
Yu-Lan SunBeijing Center for Disease Prevention and Control, Beijing, 100013, China.
Xian-Da YangJilin Provincial Center for Disease control and Prevention, Changchun, 130021, China.
Da-Peng SunShandong Provincial Center for Disease control and Prevention, Jinan, 250014, China.
Shao-Jian CaiFujian Provincial Center for Disease control and Prevention, Fuzhou, 350001, China.
Xiu-Xu YangBeijing Institute of Biotechnology, Beijing, 100071, China.
Idrissa KamaraThe Ministry of Health and Sanitation, Freetown, Sierra Leone.
Abdul KamaraThe Ministry of Health and Sanitation, Freetown, Sierra Leone.
Matt LebbyThe Ministry of Health and Sanitation, Freetown, Sierra Leone.
Brima KargboThe Ministry of Health and Sanitation, Freetown, Sierra Leone.
Patricia OngpinUNAIDS, Freetown, Sierra Leone.
Xiao-Ping DongNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing, 102206, China.
Yue-Long ShuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing, 102206, China.
Wen-Bo XuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing, 102206, China.
Gui-Zhen WuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing, 102206, China.
Michael GbounUNAIDS, Freetown, Sierra Leone.
George F GaoNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing, 102206, China. gaofu@chinacdc.cn.

Funding

National Mega project for Infectious Disease, Ministry of Science and Technology 2016ZX10004222-003National Natural Science Foundation of China 81373141National Natural Science Foundation of China 81401312National Natural Science Foundation of China 81590763
6 · The paper itself

Abstract

backgroundThe 2014-2016 Ebola virus epidemic in West Africa was the largest outbreak of Ebola virus disease (EVD) in history. Clarifying the influence of other prevalent diseases such as human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) will help improve treatment and supportive care of patients with EVD. CASE PRESENTATION: We examined HIV and hepatitis C virus (HCV) antibody prevalence among suspected EVD cases from the Sierra Leone-China Friendship Biological Safety Laboratory during the epidemic in Sierra Leone. HIV and HCV antibodies were tested in 678 EVD-negative samples by enzyme-linked immunosorbent assay. A high HIV prevalence (17.6%) and low HCV prevalence (0.22%) were observed among the suspected cases. Notably, we found decreased HIV positive rates among the suspected cases over the course of the epidemic. This suggests a potentially beneficial effect of an improved public health system after assistance from the World Health Organization and other international aid organizations.

conclusionsThis EVD epidemic had a considerable impact on the public health system and influenced the prevalence of HIV found among suspected cases in Sierra Leone, but also provided an opportunity to establish a better surveillance network for infectious diseases.

Indexed as

AdolescentAdultChildChild, PreschoolCross-Sectional StudiesEpidemicsFemaleHemorrhagic Fever, EbolaHIV InfectionsHumansInfantInfant, NewbornMaleMiddle AgedPrevalenceSierra LeoneEbolaHCVHIVPrevalenceSierra Leone

Identifiers

PMID30827277
PMCPMC6398227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.